The estimated Net Worth of Peter Wijngaard is at least 7.13 千$ dollars as of 24 November 2023. Peter Wijngaard owns over 5,000 units of Hepion Pharmaceuticals Inc stock worth over 7,126$ and over the last 5 years he sold HEPA stock worth over 0$. In addition, he makes 0$ as Independent Director at Hepion Pharmaceuticals Inc.
Peter has made over 5 trades of the Hepion Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of HEPA stock worth 15,350$ on 24 November 2023.
The largest trade he's ever made was exercising 329,439 units of Hepion Pharmaceuticals Inc stock on 27 December 2019 worth over 10,374,034$. On average, Peter trades about 36,744 units every 143 days since 2019. As of 24 November 2023 he still owns at least 9,501 units of Hepion Pharmaceuticals Inc stock.
You can see the complete history of Peter Wijngaard stock trades at the bottom of the page.
Dr. Peter Wijngaard Ph.D. serves as Independent Director of the Company. Dr. Wijngaard most recently served as Executive Vice President, Chief Development Officer at The Medicines Company (“MDCO”), where he led the overall development and global medical affairs activities for hypercholesterolemia drug candidate, inclisiran. Dr. Wijngaard was instrumental in Novartis’ US $9.7 billion acquisition of MDCO that was completed in January 2020. Previously, Dr. Wijngaard led European Medical Affairs and Development at Viropharma Inc. (which was subsequently acquired by Shire Pharmaceuticals in 2013 and is now part of The Takeda Pharmaceutical Company Limited) and held various positions at Hoffmann-La Roche, including International Medical Manager and Lifecycle Leader for the transplantation portfolio, as well as managing the Genentech alliance as Global Alliance Director. He served on the Board of Directors of Isotechnika Pharmaceuticals, Aurinia Pharmaceuticals and Ciclofilin Pharmaceuticals, which was acquired by Hepion in 2016. As an author of more than 50 scientific articles, Dr. Wijngaard has published extensively on transplant immunology and immunosuppression. He has a Ph.D. in Transplantation Immunology from Utrecht University, the Netherlands.
Peter Wijngaard is 50, he's been the Independent Director of Hepion Pharmaceuticals Inc since 2020. There are 11 older and no younger executives at Hepion Pharmaceuticals Inc. The oldest executive at Hepion Pharmaceuticals Inc is Thomas Adams, 77, who is the Independent Director.
Peter's mailing address filed with the SEC is C/O HEPION PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON, NJ, 08837.
Over the last 5 years, insiders at Hepion Pharmaceuticals Inc have traded over 0$ worth of Hepion Pharmaceuticals Inc stock and bought 119,700 units worth 247,400$ . The most active insiders traders include Gary S Jacob、Peter Wijngaard、John P Brancaccio. On average, Hepion Pharmaceuticals Inc executives and independent directors trade stock every 91 days with the average trade being worth of 7,481$. The most recent stock trade was executed by Peter Wijngaard on 24 November 2023, trading 5,000 units of HEPA stock currently worth 15,350$.
hepion pharmaceuticals, inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the united states. it is involved in developing crv431, a cyclophilin inhibitor that has completed the phase i clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of hepatitis b. the company was formerly known as contravir pharmaceuticals, inc. and changed its name to hepion pharmaceuticals, inc. in july 2019. hepion pharmaceuticals, inc. was incorporated in 2013 and is headquartered in edison, new jersey.
Hepion Pharmaceuticals Inc executives and other stock owners filed with the SEC include: